Consumer DNA kits check a limited set of known variants; they don’t diagnose disease, measure total risk, or replace clinical testing.
A consumer spit kit and a hospital genetics panel can print reports that look nearly identical on one screen. What separates them is coverage: one reads a handful of known variants, the other examines the genes a clinician would act on.
Most at-home genetic tests rely on genotyping, which checks selected, clinically relevant variants in a saliva sample instead of reading the whole genome. That design keeps reports cheap and fast, and it puts a fixed ceiling on what any single result can mean for your health.
What Can An At-Home Genetic Test Actually Tell You?
A consumer kit can show whether you carry specific variants tied to certain conditions, whether you are a carrier for selected inherited conditions, and how your DNA lines up with a set of traits. It cannot tell you whether you will develop a disease.
23andMe describes its test as qualitative genotyping of selected clinically relevant variants from adult saliva, intended for people 18 and older. Its health side covers carrier-status, health-predisposition, and wellness reports. Some of those meet FDA requirements; polygenic and research-based reports have not been reviewed by the FDA. Premium Ancestry + Health lists 50+ genetic health screenings and carrier reports, and the wider service screens for up to 95+ conditions.
Listed prices run $99 for Basic Ancestry, $149 for Premium Ancestry, and $199 for Premium Ancestry + Health, with promotional prices showing lower when checked.
Services do not test the same variants, so two of them can disagree about the same condition. A carrier result is narrower than people assume: it speaks to whether you carry selected variants for inherited conditions, not to your own future risk, fetal health, or a child’s later health.
If you are comparing services, the tested at-home genetic testing kit roundup lines up what each one screens.
Where The Results Stop: FDA Limits And The BRCA Gap
The FDA does not review most consumer health tests before they reach the market, and even the tests it does review cannot establish overall disease risk. Environment, lifestyle, and other genetic factors all feed into that number.
The FDA’s direct-to-consumer test guidance draws the split: wellness and lower-risk uses generally skip review before marketing, while tests with greater medical impact are generally reviewed for validity. Errors can still come from specimen handling, lab problems, or a report read the wrong way. A positive result is not grounds to start treatment, change a medication, or rebuild your diet on its own.
A negative result means the tested variants were not found. It does not mean every disease-linked variant is absent, and it does not cancel screening or evaluation you were already due for.
| Report Type | What It Covers | What It Doesn’t Tell You |
|---|---|---|
| Carrier status | Whether you carry selected variants for inherited conditions | Your own future risk, fetal health, or a child’s later health |
| Health predisposition | An association with higher risk for named conditions | That you have the disease or will develop it |
| Consumer BRCA test | 44 specific BRCA1 and BRCA2 mutations | Whether other BRCA mutations or genes are involved |
| Polygenic risk scores | Combined-effect scores built from research models | Any FDA-reviewed clinical meaning |
| Wellness reports | Traits such as sleep or caffeine response | Anything a clinician would treat |
The BRCA gap is where consumer testing gets riskiest. The CDC notes that the FDA-authorized DTC BRCA test checks 44 specific BRCA1 and BRCA2 mutations, while clinical testing can assess thousands of possible mutations plus additional genes. A negative consumer BRCA result therefore does not rule out hereditary cancer risk, most of all in a family where cancer already appears. That situation calls for a genetic counselor and, when indicated, clinical genetic testing.
How To Use A Kit Without Misreading The Result
Treat a kit as a question to bring to a clinician, not an answer to act on. Sample quality and the follow-up conversation decide whether the result helps you or misleads you.
The FDA is blunt about the sample: follow the collection, labeling, shipping, and registration steps exactly, because a shortcut can make the test fail outright. Run the decision past a healthcare professional before you order, so you know whether that particular test answers anything useful for your situation.
When the report arrives, take flagged results to a physician, genetic counselor, or board-certified medical geneticist. Ancestry affects how some reports read, so interpretation is not uniform.
Four habits cause most of the damage:
- Reading “increased risk” as a diagnosis.
- Reading “negative” as proof that no relevant mutation exists.
- Assuming the kit checked every gene that matters.
- Acting on a result before anyone qualified confirms it.
The sequence that holds up:
- Talk to a clinician or genetic counselor before ordering.
- Follow the kit’s collection and shipping instructions to the letter.
- Review any flagged result with a qualified professional before changing anything.
FAQs
Can A Consumer DNA Test Diagnose A Disease?
No. Consumer kits report whether selected variants linked to a condition are present, which is an association with risk rather than a diagnosis. A doctor diagnoses disease using symptoms, exams, imaging, and clinical lab work. A kit result can start that conversation, but it cannot replace it, and it should never be the only reason you begin or stop a treatment.
Does A Negative Result Mean I Have No Risk?
No. A negative result means the specific variants that kit tests for were not detected. Other variants in the same gene, other genes entirely, and non-genetic factors can still raise risk. Keep any screening your clinician recommends, and if cancer or another inherited condition runs in your family, ask about clinical genetic testing rather than leaning on a consumer report.
Are 23andMe Health Reports Reviewed By The FDA?
Some are, some are not. Certain health-predisposition and carrier reports meet FDA requirements, while polygenic-risk and research-based reports have not been reviewed by the FDA. The difference matters when you weigh a result: an unreviewed report is a research signal, not a clinical finding, and it should not drive a medical decision without a professional reading it alongside your history.
References & Sources
- U.S. Food and Drug Administration. “Direct-to-Consumer Tests.” Establishes which consumer tests get FDA review and the limits on interpreting results.
- Centers for Disease Control and Prevention. “Taking a Genetic Test on Your Own.” Documents the 44 mutations covered by the consumer BRCA test versus clinical testing.
- 23andMe. “What Health-Related Information Can I Learn From 23andMe?” Describes the report categories and which ones have FDA review.